PharmaLegacy Labs, a Shanghai pre-clinical CRO, recently formed a strategic alliance with Pasadena’s BioVinc. Both companies have expertise in musculoskeletal drug development. BioVinc has developed a bone targeting platform based on its bisphosphonate research. It sells off-the-shelf and custom probes for bone disease, while also developing its own innovative drugs. PharmaLegacy offers CRO services in a number of areas, including bone/orthopedics.
